Crofelemer · Mytesi
Small molecule
Evidence outlook
Approved: HIV-Associated Diarrhea
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Partial signal
Also in development:Short Bowel Syndrome · Phase 2
Company guidance: regulatory filing expected mid-2027 (Jaguar Health, 16 Nov 2026). “crofelemer powder for oral solution is expected to continue to provide clinical milestones, including a planned New Drug Application (NDA) filing for crofelemer for MVID in mid-2027” Source ↗
The company’s own stated timing, shown beside the ClinicalTrials.gov estimate. Neither is a confirmed date.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
ADVENT NCT00547898 · HIV Associated Diarrhea The trial was well designed, with randomization, quadruple blinding, placebo control and 374 participants, and it used a clinical diarrhea endpoint. The FDA label reports a significantly larger clinical response with crofelemer 125 mg twice daily than with placebo (18% vs 8%, one-sided p < 0.01), and this study is the efficacy basis of the US approval. Registry: NCT00547898 | 3 | Primary Efficacy Outcome is Count of Participants With Two or Less Watery Bowel Movements Per Week During at Least Two Weeks of the Treatment Phase of the Optimal Dose of Crofelemer Compared to Placebo (31 days) 2011-01-27 | Primary Efficacy Outcome is Count of Participants With Two or Less Watery Bowel Movements Per Week During at Least Two Weeks of the Treatment Phase of the Optimal Dose of Crofelemer Compared to Placebo (31 days): Crofelemer 125Mg BID 24/136 (17.6%) vs Placebo BID 11/138 (8.0%); FDA label: clinical response 18% vs 8%, 1-sided p < 0.01 | Partial signal | link ↗ |
View 1 more trial
NCT00002408 NCT00002408 · Diarrhea, HIV Infections The study was described as randomized, double-blind, placebo-controlled and multicenter, with 300 participants planned. The registry posts no results and no key result is on file for this row. Registry: NCT00002408 | 3 | — | Results not posted; external-source review pending | Partial signal | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 3 (4)
What this study did
What this study did
What this study did
What this study did
Phase 2/3 (1)
What this study did
Phase 2 (5)
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1 (1)
What this study did
Phase 4 (3)
What this study did
What this study did
What this study did
Early phase / not applicable (2)
What this study did
What this study did
Competitive landscape
This drug's own stage for Short Bowel Syndrome: Phase 2. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Crofelemer (Mytesi): this drug | Phase 2 | Small molecule | Chloride channel (intestinal epithelium) | not yet graded | No reviewed efficacy summary in this indication | |
| Teduglutide (Gattex) | Approved | Peptide | GLP-2 receptor | Partial signal | NCT02682381: Number of Participants Who Achieved at Least a 20 Percent (%) Reduction in Weight-Normalized Average Daily Parenteral Nutrition Intravenous (PN/IV) Volume at Week 24 (Baseline through Week 24): 0.025 mg/kg/Day Teduglutide — Participant Diary: 13 Participants; Investigator Prescribed: 13 Participants | 0.05 mg/kg/Day Teduglutide — Participant Diary: 18 Participants; Investigator Prescribed: 18 Participants | Standard of Care — Participant Diary: 1 Participants; Investigator Prescribed: 2 Participants NCT00798967: Responder (Weeks 20 and 24): Teduglutide 27 subjects | Placebo 13 subjects | |
| Apraglutide | Phase 3 | Peptide | GLP-2 receptor | not yet graded | No reviewed efficacy summary in this indication |
Upcoming events
(2 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Mytesi (Crofelemer) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2026 (1)
December 2026 (1)
What to watch
2027 (1)
March 2027 (1)
What to watch
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent